Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines.
Abstract
BACKGROUND: British Sarcoma Group guidelines for the management of GIST were initially informed by those published by the European Society of Clinical Oncology. This update was written by a group of experts to includes a discussion of the highlight improvements in our knowledge of the disease and recent treatment developments. The guidelines include sections on Incidence, Aetiology, Diagnosis, including risk assessment, Treatment and Follow-up. METHODS: A careful review of the literature was performed to ensure that wherever possible recommendations are supported by the results of clinical trials or substantive retrospective reports. Areas of uncertainty are indicated appropriately. CONCLUSION: Guidelines represent a consensus view of current best clinical practice. Where appropriate, key recommendations are given and the levels of evidence and strength of recommendation gradings are those used by the European Society for Medical Oncology (ESMO).
Collections
Subject
Science & Technology
Life Sciences & Biomedicine
Oncology
KINASE INHIBITOR THERAPY
PHASE-II TRIAL
IMATINIB MESYLATE
ADJUVANT IMATINIB
CARNEY-STRATAKIS
PROGRESSION-FREE
DOSE IMATINIB
RISK
MUTATIONS
DIAGNOSIS
Research team
Sarcoma Clinical Trials
Translational Sarcoma, Melanoma and Rare Tumour Surgery
Language
eng
Date accepted
2024-03-25
License start date
2024-06-05
Citation
British Journal of Cancer, 2024,
Publisher
SPRINGERNATURE